Samsung Biologics Unveils Plant 4 Virtual Showroom, Digitization Efforts
Samsung Biologics’ recently launched Plant 4 Virtual Showroom demonstrates its latest efforts to lead the biotech industry into the digital age, resulting in greater agility and productivity to respond to client, shareholder, and partner demands. The virtual showroom will provide real-time construction updates and key features of the fourth manufacturing facility as well as specifications and services to be offered upon its completion. The company officially broke ground on this newest plant in November 2020, and will be the world’s most innovative bio-manufacturing facility upon its completion in 2023.
This new digital platform illustrates the company’s presentation of its manufacturing services as a means of improving client satisfaction—a central focus of its innovative strategy for enhancing the customer experience. The showroom also allows the company to promptly respond to clients’ inquiries online about the new plant.
Both Plant 4 and the Virtual Showroom are a direct response to an accelerated demand in the industry for both traditional and digitally enabled services. Plant 4 will provide customers with easy, secured access to information on the manufacturing quality of the company’s products that complies with current regulatory requirements. Samsung Biologics also recently launched other digital initiatives such as EQUIS, which is an electronic document and quality management system that provides clients with secure, direct access to their product quality information in real time.
Samsung Biologics’ additional digital wins include the introduction of its Virtual Exhibition Hall, an award-winning website that provides a virtual experience for clients. The company was one of the first to offer this technology after in-person trade shows and seminars were canceled earlier this year due to the COVID-19 pandemic. Furthermore, Samsung Biologics also offers access to its Live Virtual Tour to existing and prospective clients as well as regulatory inspectors. The video streaming platform provides secured access to high-definition videos with integrated documents. This capability allows users to view manufacturing operations and evaluate the company’s level of current good manufacturing practice (cGMP) compliance at any time and from any location.
With this new digital transformation initiative, Samsung Biologics is cementing its reputation of excellence by combining its business, engineering, and manufacturing expertise, ultimately helping to bring innovation to the biopharmaceutical industry.